BAJAJ BROKING

Notification
No new Notification messages
Nisus Finance Services IPO is Open!
Apply for the Nisus Finance Services IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
beta drugs limited stock

BETA DRUGS LIMITED Share Price

2242.9 0.59 (0.02%)
Dec 04 2024 03:28 PM Pharmaceuticals NSE: BETA

BETA DRUGS LIMITED Share Price Update

As of the latest trading session, BETA DRUGS LIMITED share price is currently at 2242.9, which is up by 0.59 from its previous closing. Today, the stock has fluctuated between 2216.35 and 2258.00. Over the past year, BETA DRUGS LIMITED has achieved a return of 87.65 %. In the last month alone, the return has been 13.17 %. Read More...

BETA DRUGS LIMITED Performance

Day Range

Low2216.35 High2258.00
2240.70

52 Week Range

Low 1060.05 High 2326.00
2240.70

BETA DRUGS LIMITED Share Price

81

BETA

img img img img
No Data Available

Open Price

2258.00

Prev. Close

2242.30

Volume (Shares)

1900.00

Total traded value

42.57

Upper Circuit

2690.75

Lower Circuit

1793.85

Note: The current prices & values are delayed, Login to your account for live updates.

BETA DRUGS LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 2156.27
PE Ratio (TTM) 98.26
Book Value / Share 120.67
Beta 0.85
ROE 20.67%
EPS (TTM) 22.82
Dividend Yield 0.00%
Net Profit Qtr (Cr) 0.00

BETA DRUGS LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 197.62
Operating Expense 169.87
Net Profit 21.94
Net Profit Margin (%) 11.10
Earnings Per Share (EPS) 22.82
EBITDA 35.25
Effective Tax Rate (%) 25.61
Particulars MAR 2023 (Values in Cr)
Revenue 157.87
Operating Expense 133.71
Net Profit 18.82
Net Profit Margin (%) 11.92
Earnings Per Share (EPS) 19.57
EBITDA 32.24
Effective Tax Rate (%) 25.34
Particulars MAR 2022 (Values in Cr)
Revenue 124.85
Operating Expense 105.53
Net Profit 14.25
Net Profit Margin (%) 11.41
Earnings Per Share (EPS) 14.82
EBITDA 26.04
Effective Tax Rate (%) 29.36
Particulars MAR 2021 (Values in Cr)
Revenue 79.46
Operating Expense 70.17
Net Profit 6.98
Net Profit Margin (%) 8.78
Earnings Per Share (EPS) 7.26
EBITDA 15.92
Effective Tax Rate (%) 29.35
Particulars MAR 2020 (Values in Cr)
Revenue 65.32
Operating Expense 56.79
Net Profit 7.10
Net Profit Margin (%) 10.86
Earnings Per Share (EPS) 7.49
EBITDA 12.17
Effective Tax Rate (%) 20.67
Particulars MAR 2024 (Values in Cr)
Book Value / Share 163.43
ROE % 26.03
ROCE % 31.58
Total Debt to Total Equity 0.12
EBITDA Margin 20.75
Particulars MAR 2023 (Values in Cr)
Book Value / Share 127.82
ROE % 28.55
ROCE % 32.63
Total Debt to Total Equity 0.19
EBITDA Margin 23.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 96.05
ROE % 30.85
ROCE % 34.77
Total Debt to Total Equity 0.24
EBITDA Margin 23.64
Particulars MAR 2021 (Values in Cr)
Book Value / Share 71.37
ROE % 18.64
ROCE % 21.20
Total Debt to Total Equity 0.32
EBITDA Margin 21.74
Particulars MAR 2020 (Values in Cr)
Book Value / Share 59.41
ROE % 19.22
ROCE % 19.97
Total Debt to Total Equity 0.43
EBITDA Margin 20.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 120.67
ROE % 20.67
ROCE % 26.60
Total Debt to Total Equity 0.05
EBITDA Margin 17.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share 100.12
ROE % 21.67
ROCE % 27.20
Total Debt to Total Equity 0.07
EBITDA Margin 20.42
Particulars MAR 2022 (Values in Cr)
Book Value / Share 80.57
ROE % 20.23
ROCE % 26.19
Total Debt to Total Equity 0.09
EBITDA Margin 20.86
Particulars MAR 2021 (Values in Cr)
Book Value / Share 65.96
ROE % 11.65
ROCE % 15.59
Total Debt to Total Equity 0.12
EBITDA Margin 20.04
Particulars MAR 2020 (Values in Cr)
Book Value / Share 58.71
ROE % 14.63
ROCE % 16.64
Total Debt to Total Equity 0.17
EBITDA Margin 18.63
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 28.63
Total Assets 254.09
Total Liabilities 254.09
Total Equity 157.11
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 14.33
Return on Capital (%) 21.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.16
Total Assets 198.42
Total Liabilities 198.42
Total Equity 122.88
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 15.48
Return on Capital (%) 22.11
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 17.32
Total Assets 157.85
Total Liabilities 157.85
Total Equity 92.34
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 15.72
Return on Capital (%) 22.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 10.42
Total Assets 117.50
Total Liabilities 117.50
Total Equity 68.61
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 9.97
Return on Capital (%) 14.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.38
Total Assets 107.17
Total Liabilities 107.17
Total Equity 57.11
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.78
Return on Capital (%) 12.22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 27.19
Total Assets 170.47
Total Liabilities 170.47
Total Equity 116.01
Share Outstanding 9613790
Price to Book Ratio 10.22
Return on Assets (%) 12.86
Return on Capital (%) 18.34
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.79
Total Assets 134.04
Total Liabilities 134.04
Total Equity 96.25
Share Outstanding 9613790
Price to Book Ratio 6.26
Return on Assets (%) 14.03
Return on Capital (%) 18.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 15.58
Total Assets 110.89
Total Liabilities 110.89
Total Equity 77.46
Share Outstanding 9613790
Price to Book Ratio 7.02
Return on Assets (%) 12.84
Return on Capital (%) 17.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 8.26
Total Assets 86.23
Total Liabilities 86.23
Total Equity 63.41
Share Outstanding 9613790
Price to Book Ratio 1.82
Return on Assets (%) 8.09
Return on Capital (%) 10.37
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 4.16
Total Assets 82.21
Total Liabilities 82.21
Total Equity 56.43
Share Outstanding 9613790
Price to Book Ratio 0.68
Return on Assets (%) 8.63
Return on Capital (%) 11.12
Particulars MAR 2024 (Values in Cr)
Net Income 48.75
Cash from Operations 30.93
Cash from Investing -13.97
Cash from Financing -7.48
Net change in Cash 9.46
Free Cash Flow 42.54
Particulars MAR 2023 (Values in Cr)
Net Income 41.05
Cash from Operations 23.38
Cash from Investing -19.06
Cash from Financing -2.47
Net change in Cash 1.83
Free Cash Flow 41.59
Particulars MAR 2022 (Values in Cr)
Net Income 34.30
Cash from Operations 29.62
Cash from Investing -21.75
Cash from Financing -0.97
Net change in Cash 6.89
Free Cash Flow 49.05
Particulars MAR 2021 (Values in Cr)
Net Income 15.95
Cash from Operations 18.59
Cash from Investing -5.84
Cash from Financing -7.71
Net change in Cash 5.03
Free Cash Flow 24.35
Particulars MAR 2020 (Values in Cr)
Net Income 11.97
Cash from Operations 8.41
Cash from Investing -15.05
Cash from Financing 8.72
Net change in Cash 2.08
Free Cash Flow 23.71
Particulars MAR 2024 (Values in Cr)
Net Income 29.48
Cash from Operations 21.18
Cash from Investing -11.02
Cash from Financing -0.76
Net change in Cash 9.40
Free Cash Flow 27.62
Particulars MAR 2023 (Values in Cr)
Net Income 25.20
Cash from Operations 10.22
Cash from Investing -5.81
Cash from Financing -2.19
Net change in Cash 2.21
Free Cash Flow 17.13
Particulars MAR 2022 (Values in Cr)
Net Income 20.16
Cash from Operations 18.76
Cash from Investing -12.71
Cash from Financing 1.26
Net change in Cash 7.31
Free Cash Flow 28.37
Particulars MAR 2021 (Values in Cr)
Net Income 9.88
Cash from Operations 11.59
Cash from Investing -3.15
Cash from Financing -4.34
Net change in Cash 4.10
Free Cash Flow 15.03
Particulars MAR 2020 (Values in Cr)
Net Income 8.95
Cash from Operations 6.09
Cash from Investing -14.32
Cash from Financing 9.47
Net change in Cash 1.24
Free Cash Flow 13.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 58.42 33.57 3.18 447.69 37.54 / 77.70
BLISS GVS PHARMA LTD 163.60 20.48 1.70 1722.74 92.25 / 172.40
CIPLA LTD 1534.40 26.84 4.36 123920.06 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 406.85 141.27 4.12 1197.40 145.00 / 413.80
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 58.42 50.80 9.93 447.69 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.60 45.60 7.27 2167.14 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6597.95 128.14 24.28 16494.88 4050.15 / 8139.85
BLISS GVS PHARMA LTD 163.60 21.30 1.68 1722.74 92.25 / 172.40

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 2206.20
  • 26 Days 2056.40
  • 10 Days 2155.30
  • 50 Days 1957.90
  • 12 Days 2144.70
  • 100 Days 1746.90
  • 20 Days 2113.30
  • 200 Days 1359.80
2201.53
PIVOT
First Resistance 2253.07
Second Resistance 2306.13
Third Resistance 2357.67
First Support 2148.47
Second Support 2096.93
Third Support 2043.87
RSI 63.99
MACD 88.39
Commodity Channel Index (CCI) 97.48
ADX 55.02
Williams % R -14.45

Over 1 Month

down

13.17

Over 3 Months

down

22.96

Over 6 Months

down

88.34

Over 1 Year

down

87.65

Over 3 Years

down

64.90

Over 5 Years

down

96.49

BETA DRUGS LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

BETA DRUGS LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
32.1
Promoter Holdings
66.73
FII
1.15
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Neeraj Batra Shareholding of Promoter and Promoter Group 6341663.0 65.96
Ashish Kacholia Public Shareholding 556000.0 5.78
Onkar Singh Public Shareholding 100800.0 1.05
Rahul Batra Shareholding of Promoter and Promoter Group 39650.0 0.41
Varun Batra Shareholding of Promoter and Promoter Group 33230.0 0.35
Heena Batra Shareholding of Promoter and Promoter Group 590.0 0.01
Aditi Batra Shareholding of Promoter and Promoter Group 590.0 0.01

BETA DRUGS LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About BETA DRUGS LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by BETA DRUGS LIMITED

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Beta Drugs Ltd?

Answer Field

The share price of Beta Drugs Ltd for NSE is ₹ 2242.9 and for BSE is ₹ 0.00.

What is the Market Cap of Beta Drugs Ltd?

Answer Field

The market cap of Beta Drugs Ltd for NSE is ₹ 21,56.27 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Beta Drugs Ltd?

Answer Field

The 52 Week High and Low of Beta Drugs Ltd for NSE is ₹ 2326.00 and ₹ 1060.05 and for BSE is ₹ 0.00 and ₹ 0.00.

How to Buy Beta Drugs Ltd share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Beta Drugs Ltd?

Answer Field

The 1 year returns on the stock has been 87.65%.

What is the Current Share Price of Beta Drugs Ltd?

Answer Field

Beta Drugs Ltd share price is for NSE ₹ 2242.9 & for BSE ₹ 0.00 as on Dec 04 2024 03:28 PM.

What is the Market Cap of Beta Drugs Ltd Share?

Answer Field

The market cap of Beta Drugs Ltd for NSE ₹ 21,56.27 & for BSE ₹ 0.0 as on Dec 04 2024 03:28 PM.

What is the P/E Ratio of Beta Drugs Ltd Share?

Answer Field

As on Dec 04 2024 03:28 PM the price-to-earnings (PE) ratio for Beta Drugs Ltd share is 98.26.

What is the PB ratio of Beta Drugs Ltd Share?

Answer Field

As on Dec 04 2024 03:28 PM, the price-to-book (PB) ratio for Beta Drugs Ltd share is 120.67.

How to Buy Beta Drugs Ltd Share?

Answer Field

You can trade in Beta Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Beta Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Beta Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Beta Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader